⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of CytoHub Inc. and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
CytoHub Inc.
↗San Diego, USA
CytoHub is a biotechnology company focused on regenerative medicine and cell therapy, specifically targeting cardiac regeneration. The company leverages induced pluripotent stem cell (iPSC)-derived technologies and an AI-driven platform (BioEngineAI™) to develop human mini-heart organoid models for drug discovery, disease modeling, and clinical applications.
Headquartered at JLABS in San Diego, CytoHub aims to bridge the gap between laboratory research and clinical translation. Their lead program, HeartReady™, is an iPSC-derived cardiac cell therapy currently in preclinical development for ischemic heart failure.
CLASSIFICATION
Company Type:Biotech
Therapeutic Areas:
Industry:Biotechnology
Sub-Industry:Regenerative Medicine / Cardiac Therapeutics
SIZE & FINANCIALS
Employees:1-50
Founded:2023
Ownership:private
Status:operating
FUNDING
Stage:Seed
Investors:Johnson & Johnson JLABS, NVIDIA Inception, AWS, NIH, AHA, NSF, MSU Research Foundation, Red Cedar Ventures
PIPELINE
Stage:Preclinical
Lead Drug Stage:Preclinical
Modalities:Cell therapy, iPSC-derived organoids
Active Trials:0
Trial Phases:-
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Subsidiaries:Cardia Therapeutics
Key Partnerships:Michigan State University (MSU) - Technology licensing and research collaboration, PBS Biotech - Bioreactor technology integration
COMPETITION
Position:Emerging
LEADERSHIP
Key Executives:
Rajib Biswas - CEO
Frank Teoh - VP of Engineering
Scientific Founders:Aitor Aguirre
LINKS
Website:cytohub.com
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with CytoHub Inc.. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.